Articles

Out of order: Seeing things

Many discoveries and new fields come and go (when it comes to noteworthiness and newsworthiness) in the life sciences, but perhaps the microbiome will be something of a different nature, both in terms of notoriety, complexity and impact for many years to come
Written byRandall C Willis
| 3 min read

I remember hearing that if you played a specific track on a specific Beatles album backward, you would hear someone say “Paul is dead.” I also remember almost ruining both my album and record player trying to verify this secret message.

Listening to a George Carlin album, a punchline involved someone thrusting a bag of burgers toward the hapless drive-thru staff yelling “$2.52.” It was my first literal spit-take. And since that day, I see references to 252 everywhere.

Aside from indicating how old I am with the word “album,” I recount these anecdotes to highlight the idea that patterns seem to arise suddenly, and when they do, they become impossible to ignore.

More germane to DDNews, the most recent pattern I cannot seem to shake is discussion of the microbiome.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Published In

Volume 14 - Issue 3 | March 2018

March 2018

March 2018 Issue

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A scientist in a white lab coat looking into a microscope in a brightly lit modern laboratory.
Learn how developmental and reproductive toxicology study selection supports regulatory decision-making and generates meaningful nonclinical safety data.
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue